Reports involving the class of drugs known as GLP-1 agonists — Ozempic, Mounjaro and Zepbound, to include a few — were submitted to the Food and Drug Administration (FDA), stating patients experience… [+1368 chars]Read More
FDA probes side effects of weightloss drugs The Hill
